These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35568394)

  • 21. Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults.
    Kim J; Yu H; Lee S; Paek YJ
    Tob Control; 2018 Nov; 27(Suppl 1):s74-s77. PubMed ID: 30158210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.
    Moazed F; Chun L; Matthay MA; Calfee CS; Gotts J
    Tob Control; 2018 Nov; 27(Suppl 1):s20-s25. PubMed ID: 30158203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IQOS and cigarette advertising across regulatory periods and population groups in Israel: a longitudinal analysis.
    Khayat A; Levine H; Berg CJ; Shauly-Aharonov M; Manor O; Abroms L; Romm KF; Wysota CN; Bar-Zeev Y
    Tob Control; 2024 Mar; 33(e1):e3-e10. PubMed ID: 36368887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 'I perceive it to be less harmful, I have no idea if it is or not:' a qualitative exploration of the harm perceptions of IQOS among adult users.
    East KA; Tompkins CNE; McNeill A; Hitchman SC
    Harm Reduct J; 2021 Apr; 18(1):42. PubMed ID: 33849549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IQOS - a heat-not-burn (HnB) tobacco product - chemical composition and possible impact on oxidative stress and inflammatory response. A systematic review.
    Kopa PN; Pawliczak R
    Toxicol Mech Methods; 2020 Feb; 30(2):81-87. PubMed ID: 31532297
    [No Abstract]   [Full Text] [Related]  

  • 26. Perceived relative harm of heated tobacco products (IQOS), e-cigarettes, and cigarettes among adults in Canada: Findings from the ITC Project.
    Sutanto E; Miller CR; Smith DM; O'Connor RJ; Gravely S; Hammond D; Hyland A; Cummings KM; Quah ACK; Fong GT; Agar TK; Goniewicz ML
    Tob Induc Dis; 2020; 18():81. PubMed ID: 33013277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A New Ingenious Enemy: Heat-Not-Burn Products.
    Kim SC; Friedman TC
    Tob Use Insights; 2022; 15():1179173X221076419. PubMed ID: 35237081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
    Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IQOS Marketing Strategies and Expenditures in the United States From Market Entrance in 2019 to Withdrawal in 2021.
    Duan Z; Levine H; Romm KF; Bar-Zeev Y; Abroms LC; Griffith L; Wang Y; Khayat A; Cui Y; Berg CJ
    Nicotine Tob Res; 2023 Sep; 25(11):1798-1803. PubMed ID: 37338204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
    Robichaud MO; Puryear T; Cohen JE; Kennedy RD
    Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corporate communication of the relative health risks of IQOS through a webchat service.
    Braznell S; Branston JR; Gilmore AB
    Tob Control; 2023 Aug; 32(e2):e205-e211. PubMed ID: 35241501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IQOS is not an acronym: a call to researchers and journals.
    Seidenberg A; Freeman B
    Tob Control; 2021 May; 30(3):356-358. PubMed ID: 32300026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Overview of iQOS
    Başaran R; Güven NM; Eke BC
    Turk J Pharm Sci; 2019 Sep; 16(3):371-374. PubMed ID: 32454738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbonyl emissions from a novel heated tobacco product (IQOS): comparison with an e-cigarette and a tobacco cigarette.
    Farsalinos KE; Yannovits N; Sarri T; Voudris V; Poulas K; Leischow SJ
    Addiction; 2018 Nov; 113(11):2099-2106. PubMed ID: 29920842
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Berthet A; Butty A; Rossier J; Sadowski IJ; Froidevaux P
    Sci Rep; 2022 Jun; 12(1):10314. PubMed ID: 35725999
    [No Abstract]   [Full Text] [Related]  

  • 39. IQOS marketing strategies at point-of-sales: a cross-sectional survey with retailers.
    Bar-Zeev Y; Berg CJ; Khayat A; Romm KF; Wysota CN; Abroms LC; Elbaz D; Levine H
    Tob Control; 2023 Aug; 32(e2):e198-e204. PubMed ID: 35140170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Light and mild redux: heated tobacco products' reduced exposure claims are likely to be misunderstood as reduced risk claims.
    Popova L; Lempert LK; Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s87-s95. PubMed ID: 30209208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.